ADPT
Price
$9.03
Change
-$0.24 (-2.59%)
Updated
May 9 closing price
Capitalization
1.37B
80 days until earnings call
CDXS
Price
$2.46
Change
-$0.00 (-0.00%)
Updated
May 9 closing price
Capitalization
203.8M
3 days until earnings call
Ad is loading...

ADPT vs CDXS

Header iconADPT vs CDXS Comparison
Open Charts ADPT vs CDXSBanner chart's image
Adaptive Biotechnologies
Price$9.03
Change-$0.24 (-2.59%)
Volume$1.15M
Capitalization1.37B
Codexis
Price$2.46
Change-$0.00 (-0.00%)
Volume$448.26K
Capitalization203.8M
ADPT vs CDXS Comparison Chart
Loading...
ADPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADPT vs. CDXS commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADPT is a Hold and CDXS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (ADPT: $9.03 vs. CDXS: $2.46)
Brand notoriety: ADPT: Notable vs. CDXS: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADPT: 43% vs. CDXS: 50%
Market capitalization -- ADPT: $1.37B vs. CDXS: $203.8M
ADPT [@Biotechnology] is valued at $1.37B. CDXS’s [@Biotechnology] market capitalization is $203.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADPT’s FA Score shows that 0 FA rating(s) are green whileCDXS’s FA Score has 0 green FA rating(s).

  • ADPT’s FA Score: 0 green, 5 red.
  • CDXS’s FA Score: 0 green, 5 red.
According to our system of comparison, both ADPT and CDXS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADPT’s TA Score shows that 6 TA indicator(s) are bullish while CDXS’s TA Score has 4 bullish TA indicator(s).

  • ADPT’s TA Score: 6 bullish, 4 bearish.
  • CDXS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ADPT is a better buy in the short-term than CDXS.

Price Growth

ADPT (@Biotechnology) experienced а -8.23% price change this week, while CDXS (@Biotechnology) price change was -2.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Reported Earning Dates

ADPT is expected to report earnings on Jul 30, 2025.

CDXS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADPT($1.37B) has a higher market cap than CDXS($204M). ADPT YTD gains are higher at: 50.626 vs. CDXS (-48.428). CDXS has higher annual earnings (EBITDA): -53.41M vs. ADPT (-128.76M). ADPT has more cash in the bank: 222M vs. CDXS (73.5M). CDXS has less debt than ADPT: CDXS (59.9M) vs ADPT (89.4M). ADPT has higher revenues than CDXS: ADPT (179M) vs CDXS (59.3M).
ADPTCDXSADPT / CDXS
Capitalization1.37B204M673%
EBITDA-128.76M-53.41M241%
Gain YTD50.626-48.428-105%
P/E RatioN/AN/A-
Revenue179M59.3M302%
Total Cash222M73.5M302%
Total Debt89.4M59.9M149%
FUNDAMENTALS RATINGS
ADPT vs CDXS: Fundamental Ratings
ADPT
CDXS
OUTLOOK RATING
1..100
3823
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
43
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9394
PRICE GROWTH RATING
1..100
3664
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (43) in the Chemicals Specialty industry is in the same range as ADPT (62) in the Hospital Or Nursing Management industry. This means that CDXS’s stock grew similarly to ADPT’s over the last 12 months.

CDXS's Profit vs Risk Rating (100) in the Chemicals Specialty industry is in the same range as ADPT (100) in the Hospital Or Nursing Management industry. This means that CDXS’s stock grew similarly to ADPT’s over the last 12 months.

ADPT's SMR Rating (93) in the Hospital Or Nursing Management industry is in the same range as CDXS (94) in the Chemicals Specialty industry. This means that ADPT’s stock grew similarly to CDXS’s over the last 12 months.

ADPT's Price Growth Rating (36) in the Hospital Or Nursing Management industry is in the same range as CDXS (64) in the Chemicals Specialty industry. This means that ADPT’s stock grew similarly to CDXS’s over the last 12 months.

ADPT's P/E Growth Rating (100) in the Hospital Or Nursing Management industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that ADPT’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADPTCDXS
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
77%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 12 days ago
87%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
Aroon
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 5 days ago
90%
View a ticker or compare two or three
Ad is loading...
ADPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLDAX30.260.77
+2.61%
Gabelli Gold A
HSZYX6.120.05
+0.82%
NexPoint Climate Tech Y
TRGVX17.660.08
+0.46%
T. Rowe Price Glbl Val Eq
GIEYX15.470.07
+0.45%
GuideStone Funds International Eq Instl
JHDCX18.030.02
+0.11%
JPMorgan Hedged Equity 2 C